Skip to main content

Lexicon to Raise Nearly $40M Financing

NEW YORK (GenomeWeb News) - Lexicon Genetics today said it has entered into agreements with unspecified investors to purchase up to 10,582,011 shares of its stock.
 
The Woodlands, Texas-based biopharmaceutical company said "select institutional investors" agreed to purchase the stock at a price of $3.78 per share, and that it expects net proceeds of up to $37.5 million.
 
The agents for the placement were Banc of America Securities and Lazard Capital Markets.
 
Lexicon studies gene function and behavior to help in the development of
small molecule, antibody, and protein drugs.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.